Search - tctmd.com

Displaying 141 - 160 of 923

Sort: Relevancy | Date

Presentation TCT 2024

TCT 475: Long-Term Outcomes of Simultaneous Interventional Treatment for Hypertrophic Obstructive Cardiomyopathy and Concomitant Coronary Artery Disease

Presenter: Stanislav Fanta

October 27, 2024

Presentation TCT 2024

TCT 478: Socioeconomic Disparities in Patients Undergoing Alcohol Septal Ablation in Hypertrophic Obstructive Cardiomyopathy: A 5-Year National Experience

Presenter: Himaja Dutt Chigurupati

October 27, 2024

Presentation TCT 2024

TCT 479: Incomplete Resolution of Left Ventricular Outflow Tract Gradient After Alcohol Septal Ablation Is Predictive of Need for Reintervention in Hypertrophic Obstructive Cardiomyopathy: A Retrospective Cohort Study

Presenter: Kylie Duckworth

October 27, 2024

Presentation TCT 2024

TCT 477: Procedural Outcomes in 25 Years of Alcohol Septal Ablations at a Tertiary Level Medical Center

Presenter: Nikhil Rao

October 27, 2024

Presentation TCT 2024

TCT 879: Perioperative and In-Hospital Outcomes of Dilated Cardiomyopathy in Patients Undergoing Transcatheter Aortic Valve Replacement: A Large Cross-Sectional Study Using National Inpatient Sample

Presenter: Ankur Singla

October 27, 2024

News Daily News

Heart Failure and Cancer: HFSA Statement Explores the Interplay

Caitlin E. Cox

October 24, 2024

News Conference News HFSA 2024

Biomarker and Echo Data Bolster Vutrisiran’s Promise in ATTR-CM

L.A. McKeown

October 04, 2024

News Conference News HFSA 2024

EXPANDed: Atrial Secondary MR Patients Get Clinical Benefit From TEER

Caitlin E. Cox

October 03, 2024

News Conference News HFSA 2024

‘Metabolic Accelerator’ Cuts Weight, Not Muscle in HFpEF: HuMAIN-HF

Michael O'Riordan

October 03, 2024

News Conference News HFSA 2024

‘Global Efficacy’ of Aficamten for Obstructive Disease Shown in SEQUOIA-HCM

L.A. McKeown

October 02, 2024

News Conference News HFSA 2024

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

Todd Neale

October 01, 2024

News Daily News

Subcutaneous Furosemide Enables HF Patients to Address Congestion at Home

Caitlin E. Cox

September 16, 2024

News Daily News

Tricuspid TEER Continues to Offer Benefits Through 3 Years: TRILUMINATE

Caitlin E. Cox

September 12, 2024

Podcast TCTMD Talking Points

The ATTRibute-CM Trial

September 04, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2024

Caitlin E. Cox

September 03, 2024

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

News Opinion CV Team Dispatch

September 2024 Dispatch for the CV Team

L.A. McKeown

September 01, 2024

News Conference News ESC 2024

RESHAPE-HF2 Is a Win for MitraClip in FMR—Not Everyone’s On Board

Shelley Wood

August 31, 2024

News Conference News ESC 2024

Tri.Fr Trial Affirms Quality-of-Life Impact of Tricuspid TEER

Todd Neale

August 31, 2024

News Conference News ESC 2024

HELIOS-B: Novel ‘Silencer’ Agent Reduces Death, CV Events in ATTR-CM

L.A. McKeown

August 30, 2024

Advertisement

TCT 475: Long-Term Outcomes of Simultaneous Interventional Treatment for Hypertrophic Obstructive Cardiomyopathy and Concomitant Coronary Artery Disease

TCT 478: Socioeconomic Disparities in Patients Undergoing Alcohol Septal Ablation in Hypertrophic Obstructive Cardiomyopathy: A 5-Year National Experience

TCT 479: Incomplete Resolution of Left Ventricular Outflow Tract Gradient After Alcohol Septal Ablation Is Predictive of Need for Reintervention in Hypertrophic Obstructive Cardiomyopathy: A Retrospective Cohort Study

TCT 477: Procedural Outcomes in 25 Years of Alcohol Septal Ablations at a Tertiary Level Medical Center

TCT 879: Perioperative and In-Hospital Outcomes of Dilated Cardiomyopathy in Patients Undergoing Transcatheter Aortic Valve Replacement: A Large Cross-Sectional Study Using National Inpatient Sample

Heart Failure and Cancer: HFSA Statement Explores the Interplay

Biomarker and Echo Data Bolster Vutrisiran’s Promise in ATTR-CM

EXPANDed: Atrial Secondary MR Patients Get Clinical Benefit From TEER

‘Metabolic Accelerator’ Cuts Weight, Not Muscle in HFpEF: HuMAIN-HF

‘Global Efficacy’ of Aficamten for Obstructive Disease Shown in SEQUOIA-HCM

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

Subcutaneous Furosemide Enables HF Patients to Address Congestion at Home

Tricuspid TEER Continues to Offer Benefits Through 3 Years: TRILUMINATE

The ATTRibute-CM Trial

TCTMD’s Top 10 Most Popular Stories for August 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

September 2024 Dispatch for the CV Team

RESHAPE-HF2 Is a Win for MitraClip in FMR—Not Everyone’s On Board

Tri.Fr Trial Affirms Quality-of-Life Impact of Tricuspid TEER

HELIOS-B: Novel ‘Silencer’ Agent Reduces Death, CV Events in ATTR-CM

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content